What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?

[1]  F. Barkhof,et al.  Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease , 2021, JAMA neurology.

[2]  F. Elahi,et al.  An introduction to therapeutic approaches to vascular cognitive impairment , 2021, Cerebral circulation - cognition and behavior.

[3]  J. Manly,et al.  What the Aducanumab Approval Reveals About Alzheimer Disease Research. , 2021, JAMA neurology.

[4]  R. Howard,et al.  Can we learn lessons from the FDA’s approval of aducanumab? , 2021, Nature Reviews Neurology.

[5]  J. Cummings.  Why aducanumab is important , 2021, Nature Medicine.

[6]  A. Toga,et al.  How Will Aducanumab Approval Impact AD Research? , 2021, The Journal of Prevention of Alzheimer's Disease.

[7]  A. Atri,et al.  Aducanumab: Appropriate Use Recommendations , 2021, The Journal of Prevention of Alzheimer's Disease.

[8]  Eric E. Smith,et al.  Off-label use of aducanumab for cerebral amyloid angiopathy , 2021, The Lancet Neurology.

[9]  C. Brayne,et al.  Aducanumab for Alzheimer’s disease? , 2021, BMJ.

[10]  R. Kalaria,et al.  Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease , 2021, The American journal of pathology.

[11]  David T. Jones,et al.  Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[12]  Eric E. Smith,et al.  Vascular dysfunction—The disregarded partner of Alzheimer's disease , 2019, Alzheimer's & Dementia.

[13]  Nick C Fox,et al.  Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis , 2012, The Lancet Neurology.